111, Inc. reports on a China-based, tech-enabled healthcare platform that connects consumers, pharmacies and healthcare partners through online and offline channels. The company’s recurring updates cover its B2B pharmaceutical sourcing platform, B2C online retail pharmacy activity, internet hospital services through 1 Clinic, and cloud-based services for offline pharmacies.
Company news also focuses on unaudited financial results, gross segment profit, operating expenses, cash flow, B2B gross margin trends and the transition toward an asset-light fulfillment partnership model. Other recurring topics include digital tools, supply-chain efficiency, drug commercialization services and Nasdaq ADR listing compliance matters.
111 (YI) established a three-member independent board committee to evaluate a preliminary, non-binding proposal and other potential strategic alternatives.
The proposal letter is dated September 16, 2026. The board has made no decision on the proposal or any alternative strategic option.
111 (YI) has received an unsolicited, preliminary and non-binding proposal dated September 16, 2026 from a buyer group to take the company private.
The buyer group consists of co-founders and co-chairmen Dr. Gang Yu and Mr. Junling Liu, who is also chief executive officer, together with Huadeng Tech BioArray Ventures Ltd. The proposal contemplates acquiring all outstanding Class A ordinary shares not already owned by the buyer group, including shares represented by American depositary shares (ADSs), for US$0.226 per Class A Share or US$4.52 per ADS in cash.
The buyer group indicates that the consideration would be funded with equity capital, including rollover equity and cash contributions from the sponsor or its affiliates. The board states it has only just received the proposal, has not evaluated it, and there is no assurance any definitive offer, agreement or transaction will result.
111 (YI) reported second quarter 2026 net revenue of RMB2.3 billion, down 28.3% year-over-year, as it continues a strategic shift to a more asset-light, platform-oriented model and exits underperforming subsidiaries.
Total marketplace service revenue for the first half of 2026 grew 18.2% year-over-year, while net revenue from promotional products rose to RMB60.7 million, up 121%, with gross profit from these products up 120%. Fulfillment expenses fell to RMB63.6 million, down 29.5%, improving to 2.76% of net revenue. Total operating expenses were RMB155.5 million, a 16.1% decline. However, gross segment profit fell 28.6% to RMB132.3 million, and the company swung to a loss from operations of RMB23.2 million and a net loss of RMB31.7 million. Cash, restricted cash and short-term investments declined to RMB381.1 million at June 30, 2026.
111 (NASDAQ:YI) reported unaudited Q1 2026 results, highlighting an ongoing shift to an asset-light, platform-driven model.
Net revenue was RMB2.4 billion, down 33.1% year-over-year, while total marketplace service revenue rose 24.7%. Promotional product revenue grew 70.2% and gross profit 75.0%.
Fulfillment expenses fell 34.6% to RMB61.2 million and improved to 2.6% of net revenue. The company posted a RMB20.0 million operating loss and RMB26.8 million net loss. Cash, restricted cash and short-term investments totaled RMB396.6 million, with RMB0.95 billion owed to 1 Pharmacy Technology investors under redemption arrangements.
111, Inc. (NASDAQ: YI) reported Q4 and fiscal 2025 unaudited results on April 9, 2026, after executing an asset-light shift and divesting several subsidiaries.
Key highlights: FY2025 net revenues RMB12.6B (-12.8% YoY); Q4 net revenues RMB2.8B (-26.7% YoY); maintained non-GAAP operating profitability for Q4 and FY; positive operating cash flow in Q4 (RMB29.9M) and FY (RMB119.1M); B2B gross margin expanded to 5.6% in Q4 (+60 bps) and to 5.5% FY (+10 bps); cash and equivalents RMB611.3M (+17.9%).
111, Inc. (NASDAQ: YI) reported third quarter 2025 unaudited results, highlighting a strategic shift to an asset-light model and improved cash generation.
Key metrics: net revenues RMB3.0 billion (down 16.7% YoY), gross segment profit RMB178.0 million (down 15.5% YoY), net cash from operating activities RMB38.1 million, and positive operating cash flow YTD RMB89.3 million. The company completed divestitures of three self-operated subsidiaries to become fulfillment partners, citing strengthened liquidity and profitability. The MANTIANXING supply-chain initiative reported GMV +20.5% and customer count +31.0% vs Q2.
111, Inc. (NASDAQ: YI) reported Q2 2025 financial results showing maintained operational profitability despite challenging market conditions. Net revenues decreased 6.4% to RMB3.2 billion (US$447.5 million) compared to the same quarter last year. The company achieved a 9.3% reduction in operating expenses to RMB185.3 million, representing 5.8% of net revenues, an improvement of 20 basis points year-over-year.
Key operational highlights include a 53.6% increase in marketing promotional products sales and 19% growth in customer count. The company's 'MANTIANXING' initiative expanded to 19 fulfillment centers, generating RMB355 million in inventory value with GMV increasing 58.2% quarter-over-quarter. However, the company reported a net loss of RMB7.3 million (US$1.0 million), compared to RMB2.1 million in Q2 2024.
111, Inc. (NASDAQ: YI) has reported its Q4 and fiscal year 2024 financial results, marking significant milestones with its first-ever annual operating profit and positive operating cash flow. The company achieved income from operations of RMB2.1 million in 2024, a remarkable turnaround from an RMB350.1 million loss in 2023.
Q4 2024 net revenues were RMB3.8 billion (US$527.1 million), showing a 6.3% decrease YoY due to macroeconomic challenges. However, operating efficiency improved significantly, with total operating expenses decreasing by 470 basis points to 5.5% of net revenues.
For fiscal year 2024, net revenues reached RMB14.4 billion (US$2.0 billion), with operating expenses decreasing 230 basis points to 5.7%. The company generated positive operating cash flow of RMB263.0 million, ending the year with cash and equivalents of RMB518.3 million.
111, Inc. (NASDAQ: YI) has announced its participation in an upcoming fireside chat with Water Tower Research on March 26, 2025 at 11:00 a.m. ET. The event will feature Co-Founder, Chairman, and CEO Junling Liu discussing several key topics:
- Q4 2024 earnings results (to be reported on March 20, 2024)
- Company priorities and goals for 2025
- Updated overview of the macroenvironment
The tech-enabled healthcare platform company, focused on digitally transforming China's healthcare value chain, will host this listen-only event with WTR's senior research analyst Robert Sassoon. A replay will be available in the events section of 111's investor relations website at http://ir.111.com.cn/.